EN DE

BEBO Health SA (MLBBO) Fair Value & Analysis

Consumer Cyclical · FR · Market cap €131M · ISIN CH1148983609

What is BEBO Health SA really worth?

BH BEBO Health SA MLBBO · PA
Price€0.1840
Fair Value€0.0170
Upside−90.8%
Quality38/100

Below-average quality, and trading another 982% above our fair value of €0.0170.

Watch BEBO Health SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

Low debt

Risks

!Mixed Growth (revenue 5y +62.1 %/yr)
!Thin margins · 0.0% net margin
!Trails peers (1/9)
!Evidence only low, so the estimate is less certain
Evidence: Low Range €0.0085 – €0.0170

Fair value as of: Aug 14, 2026

From 7 valuation models · updated 18 days ago

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case (€0.0170). The favourable scenario is already priced in.
  • Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • A fairly wide model range (€0.0085 to €0.0170) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

€2.60 €0.1400 Fair Value €0.0170 Jan 2022 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 14, 2026.

How to read this chart

56‑month range €0.1400 – €2.60 · fair‑value band €0.0085 – €0.0170 · the €0.1840 price screens above the €0.0170 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 14, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

BEBO Health SA (MLBBO) currently trades at €0.1840, while our model-based Fair Value estimate is €0.0170, implying the stock looks roughly 982.3% overvalued today. The Quality Score stands at 38/100 (below-average quality), in the Consumer Cyclical sector. Bull case: the Multiples group reads highest at a median of €0.0200 per share, and 0 of the 7 models we run sit above the €0.1840 price. Bear case: the Earnings-Based group reads lowest at €0.0100, and 7 of the 7 models stay below the price. Evidence for this calculation is low.

Net debt stands at €1.7M. Fundamentals as of Aug 14, 2026

Our scenario range runs from €0.0085 (bear case) to €0.0170 (bull case); at €0.1840, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Consumer Cyclical peers we cover trades at −12% fair-value upside, at −91%, MLBBO screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
EPV best evidence €0.0100 €0.0100 €0.0100 74
ROIC Compounder €0.0100 €0.0100 €0.0100 70
Residual Income €0.0100 €0.0100 €0.0100 68
All 7 models by family
Earnings-Based
EPV best evidence €0.0100 €0.0100 €0.0100 74
Multiples
EV/EBIT €0.0200 €0.0200 €0.0300 66
EV/EBITDA €0.0100 €0.0200 €0.0200 67
EV/Revenue €0.0100 €0.0200 €0.0200 54
Asset-Based
NCAV (Graham) €0.0100 €0.0100 €0.0200 52
Economic Profit
Residual Income €0.0100 €0.0100 €0.0100 68
ROIC Compounder €0.0100 €0.0100 €0.0100 70

Widest divergence: Multiples (€0.0200) versus Earnings-Based (€0.0100). Highest evidence: EPV (74).

Notify me when MLBBO reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Net margin 0.2% FY2025
Return on assets (EBIT) 4.7% avg 5y
Net debt €1.7M FY2025

Figures from reported company fundamentals · as of Aug 14, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 38/100

Of which business quality 40 · Market factors (momentum, volatility) 10

Profitability 38
Margins and returns on capital today
Quality Growth 49
Are margins and returns improving?
Fin. Strength 65
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 9
Price trend over the last 3–12 months (market factor)
52W Momentum 25
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

BEBO Health SA operates an e-commerce portal for products related to health, sports, and well-being. The company was founded in 2019 and is based in Geneva, Switzerland. BEBO Health SA operates as a subsidiary of CES Management SA.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

BEBO Health SA reported revenue of CHF 23.6M in FY2025 versus CHF 5.5M in FY2021, a compound +44.2%/yr. Reported net income was CHF 39.2K in FY2025, compounding −9.4%/yr from FY2021.

Growth Quality 64/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
€23.6M
Latest YoY
+278.3%
Avg. revenue growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+55.8%
Avg. revenue growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+62.1%
Avg. revenue growth/yr (6Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+68.7%
Value creation/yr (5Y) Earnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
−67.2% (−67.2 + 0.0)
Revenue +44.2%/yr
FY21 CHF 5.5M
FY22 CHF 6.2M
FY23 CHF 5.0M
FY24 CHF 6.2M
FY25 CHF 23.6M
Net income −9.4%/yr
FY21 CHF 58.1K
FY22 CHF 81.3K
FY23 CHF 11.7K
FY24 CHF 81.3K
FY25 CHF 39.2K

MLBBO screens 982% overvalued. Compare with Alimentation Couche-Tard Inc →

Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "BEBO Health SA Fair Value". https://www.fairvalue-calculator.com/stock/MLBBO

Peer Group

Specialty Retail · 231 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 38 · Bottom 25%
Fair Value upside −91% · Bottom 25%
Return on assets 0% · Below median
Net margin (TTM) 0% · Below median
Operating margin (TTM) 0% · Below median
Revenue growth 0% · Below median
Debt / equity 0.01× · Lower than median

Valuation Multiples vs Specialty Retail median · lower = cheaper

P/B 10.35× · Pricier than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 30
FUTURE0 · sector 25
PAST0 · sector 26
HEALTH100 · sector 96
DIVIDEND0 · sector 58

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Retail stocks, each showing price versus our Fair Value estimate (as of Aug 14, 2026).

Stock Price Fair Value vs Fair Value
Alimentation Couche-Tard Inc ATD C$89.93 C$104.32 +16%
Casey's General Stores, Inc CASY $755.47 $398.90 −47%
Williams-Sonoma, Inc WSM $235.09 $162.63 −31%
Ulta Beauty, Inc ULTA $543.19 $475.40 −12%
DICK'S Sporting Goods, Inc DKS $202.66 $181.10 −11%
Best Buy Co BBY $82.44 $108.04 +31%
China Tourism Group 601888 ¥54.97 ¥40.40 −27%
Tractor Supply Company TSCO $34.72 $35.52 +2%
Five Below, Inc FIVE $259.41 $117.29 −55%
Murphy USA Inc MUSA $574.12 $423.35 −26%

Compare BEBO Health SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Cyclical stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Fama-French 3-Factor Model Calculator Run the Fama-French 3-factor model in seconds: expected return from the market, size and value factors - free, with formula, betas and an example. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is BEBO Health SA (MLBBO) overvalued or undervalued?
As of Aug 14, 2026, our model estimates a fair value of €0.0170 versus a price of €0.1840, about −91% upside (overvalued).
What is the fair value of MLBBO?
Our model-based fair value for BEBO Health SA is €0.0170 (as of Aug 14, 2026), built from audited fundamentals. The current price: €0.1840.
What is the quality score of MLBBO?
BEBO Health SA has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the net profit margin of MLBBO?
The net profit margin of BEBO Health SA is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.
Free · no account needed

Watch BEBO Health SA in the live analysis

One click puts BEBO Health SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.